Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?
[Do phosphodiesterase type 5 inhibitors generics enhance discontinuation due to price with patients suffering from erectile dysfunction?] Prog Urol. 2019 May 28;: Authors: Baydaroglu E, Eschwège P, Hubert J, El Osta R Abstract INTRODUCTION: Phosphodiesterase type 5 inhibitors (PDE5i) are the first-line treatment of erectile dyfunction (ED). Cost of PDE5i is not covered by health insurance company in France. Few studies have examined the potential impact of the introduction of generic products of PDE5i on price non-compliance. The aim of the study was to compare the non-compliance rate because of price among patients treated for DE with generics of PDE5i and those treated with brand-name medications. METHOD: A multi-centre, cross-sectional, study that analyzed the answers to a questionnaire distributed to consultations in four hospitals for a period of twenty-eight months. Patients were included if they had DE treated for at least 3 months. The proportions between the two groups were compared with a non-inferiority test Wilcoxon-Mann-Whitney. RESULTS: One hundred and seventy-seven questionnaires were analyzed. Patients treated with generic PDE5i were significantly (α
Conclusions Postradical prostatectomy ED has been demonstrated to improve with microsurgical interventions. In the coming years, innovation will continue and collaboration between plastic surgeons and urologists will allow us to tackle this common and difficult problem.
Conditions: Erectile Dysfunction; Extracorporeal Shockwave Therapy; Radical Prostatectomy Intervention: Device: Low Intensity Extracorporeal Shockwave Therapy (LI-ESWT) Sponsor: Odense University Hospital Not yet recruiting
OCT, Eastern Europe’s leading CRO, partners with UK-based Futura Medical; completes clinical trial enrollment for MED2002, a topical gel developed to treat erectile dysfunction.(PRWeb August 16, 2019)Read the full story at https://www.prweb.com/releases/oct_clinical_trials_successfully_recruits_700_patients_for_phase_iii_erectile_dysfunction_study/prweb16505766.htm
Conclusion. Fixed partner, ejaculation, masturbation are protective factors for sexual dysfunction. Erectile dysfunction, orgasmic, and infrequent sex dysfunction are predictors of sexual dysfunction. Level of Evidence: 3
Boston Scientific is releasing its new Tactra malleable penile prosthesis, a device that provides a new option for treating erectile dysfunction. It is designed to reproduce a natural erection thanks to a dual-layer silicone construction and Nitinol ...
TUESDAY, Aug. 13, 2019 -- Erectile dysfunction (ED) may negatively affect work productivity and health-related quality of life (HRQoL), according to a study published online Aug. 6 in the International Journal of Clinical Practice. Irwin Goldstein,...
(Natural News) Taking L-arginine by itself may not be enough to improve the symptoms of erectile dysfunction. But researchers suggest that L-arginine could be taken alongside pycnogenol, thereby increasing the beneficial effects of the two natural compounds on men who have impotence. The body turns L-arginine into nitric oxide. The latter substance serves as a neurotransmitter in the brain, spurs the cardiac muscle...
CONCLUSION: Hemiablation HIFU is an alternative to whole gland therapy in patients with unilateral radio- recurrent prostate cancer, which offers limited urinary and rectal morbidity, and preserves functional outcomes. LEVEL OF EVIDENCE: 3. PMID: 31400963 [PubMed - as supplied by publisher]
Conclusion CTS occurs in most patients with hATTR amyloidosis and frequently precedes the hATTR diagnosis. Most patients with CTS preceding hATTR diagnosis have systemic features. Recognizing systemic features at the time of CTS presentation may help in early diagnosis of hATTR amyloidosis.
Adding a mix of nuts to a typical Western diet improves orgasmic function and sexual desire in healthy men aged 18 to 35 years, but no change in erectile dysfunction and intercourse satisfaction was found.Medscape Medical News